Sandrine Boyault
Overview
Explore the profile of Sandrine Boyault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
12483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, et al.
Breast Cancer Res
. 2025 Feb;
27(1):25.
PMID: 39972319
Background: Apolipoprotein Ɛ4 genotype (APOE4) has been associated with cancer-related cognitive impairment, but its interaction with treatments remains unclear. This longitudinal study aims to evaluate the association between APOE4 and...
2.
Pagliuca M, Havas J, Thomas E, Drouet Y, Soldato D, Franzoi M, et al.
J Natl Cancer Inst
. 2024 Sep;
117(1):89-102.
PMID: 39250750
Background: Fatigue, cognitive impairment, anxiety, depression, and sleep disturbance are cancer-related behavioral symptoms that may persist years after early-stage breast cancer, affecting quality of life. We aimed to generate a...
3.
Piffoux M, Jacquemin J, Petera M, Durand S, Abila A, Centeno D, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4654-4666.
PMID: 39106085
Purpose: Long-term treatment-related toxicities, such as neurologic and metabolic toxicities, are major issues in breast cancer. We investigated the interest of metabolomic profiling to predict toxicities. Experimental Design: Untargeted high-resolution...
4.
Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, et al.
Cancer Med
. 2024 Mar;
13(7):e7115.
PMID: 38553950
Introduction: The objective was to determine the added value of comprehensive molecular profile by whole-exome and RNA sequencing (WES/RNA-Seq) in advanced and refractory cancer patients who had no molecular-based treatment...
5.
Tredan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444551
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on...
6.
Sertier A, Ferrari A, Pommier R, Treilleux I, Boyault S, Devouassoux-Shisheboran M, et al.
Cancer Res Commun
. 2023 Jun;
3(5):830-841.
PMID: 37377900
Significance: We have provided a detailed characterization of the genomic landscape of CS and identified EMT as a common mechanism associated with phenotypic divergence, linking CS heterogeneity to genetic, transcriptomic,...
7.
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, et al.
Nat Genet
. 2023 Mar;
55(4):607-618.
PMID: 36928603
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using...
8.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, et al.
Nature
. 2022 Sep;
610(7931):343-348.
PMID: 36071165
Cancer progression is driven in part by genomic alterations. The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations, leading to the concept that generation of genomic profiling...
9.
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, et al.
Clin Cancer Res
. 2022 Jul;
28(18):4018-4026.
PMID: 35802649
Purpose: Targeted therapies (TT) and immune checkpoint blockers (ICB) have revolutionized the approach to non-small cell lung cancer (NSCLC) treatment in the era of precision medicine. Their impact as switch...
10.
Ortiz-Cuaran S, Swalduz A, Foy J, Marteau S, Morel A, Fauvet F, et al.
Eur J Cancer
. 2022 May;
169:106-122.
PMID: 35550950
Introduction: Epithelial-to-mesenchymal transition (EMT) is associated with tumor aggressiveness, drug resistance, and poor survival in non-small cell lung cancer (NSCLC) and other cancers. The identification of immune-checkpoint ligands (ICPLs) associated...